Recombinant Human Lumican Protein, CF

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human Lumican Protein, CF Summary

• Details of Functionality: Measured by the ability of the immobilized protein to support the adhesion of BCE C/D‑1b bovine corneal endothelial cells. When 5 x 10⁴ cells per well are added to Recombinant Human Lumican coated plates (10 μg/mL, 100 μL/well), >35% will adhere after 50 minutes at 37 °C.
  Optimal dilutions should be determined by each laboratory for each application.
• Source: Mouse myeloma cell line, NS0-derived human Lumican protein
  Gln19-Asn338, with a C-terminal 6-His tag
• Accession #: P51884
• N-terminal Sequence: No results obtained: Gln19 predicted
• Protein/Peptide Type: Recombinant Proteins
• Gene: LUM
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <1.0 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 37.5 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 55-65 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 200 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human Lumican Protein, CF

• KSPG lumican
• LDC
• LUM
• lumican proteoglycan
• Lumican
• SLRR2D
• SLRR2DLDCKeratan sulfate proteoglycan lumican

Background

Lumican is a 40 kDa member of the family of small leucine-rich repeat proteoglycans (SLRPs) and the class II subfamily (1). Human Lumican is synthesized as a 338 amino acid (aa) precursor that contains an 18 aa signal sequence and a 320 aa mature chain (SwissProt #: P51884). The mature chain contains a negatively charged N-terminal domain containing sulfated tyrosine and disulfide bonds, 12 leucine-rich repeats (LRRs), four potential sites of N-linked glycosylation, and a carboxyl terminal domain containing two conserved cysteines (1). Mature human Lumican is 88%, 87%, and 70% aa identical to mature mouse, rat, and chick Lumican, respectively. SLRPs constitute an important fraction of noncollagenous extracellular matrix proteins (ECM) proteins (1, 2). Lumican is expressed in a variety of tissues, including skin, artery, lung, cornea, kidney, bone, aorta, and articular cartilage (1). Lumican’s role in vivo has been found using Lumican null mice. These mice have functional deficits including corneal opacity as well as skin and tendon fragility associated with disorganized and loosely packed collagen fibers
(1, 3-6). The abnormal connective tissue phenotype seen in the Lumican null mice shows the importance of the role of Lumican in collagen fibrillogenesis (1). In addition to the control of collagen fibril assembly, Lumican has been shown to play a role in the regulation of cell proliferation (7, 8), migration (8, 9), and adhesion (9). Lumican’s over-expression has been reported in carcinoid tumor, breast, colorectal, neuroendocrine, uterine cervical and pancreatic cancers (10).

1. Nikitovic, D. et al. (2008) IUBMB Life 60:818.
2. Blochberger, T.C. et al. (1992) J. Biol. Chem. 267:347.
3. Chakravarti, S. et al. (1998) J. Cell Biol. 141:1277.
4. Chakravarti, S. et al. (2000) Invest. Ophthalmol. Vis. Sci. 41:3365.
5. Jepsen, K.J. et al. (2002) J. Biol. Chem. 277:35532.
6. Chakravarti, S. et al. (2003) Invest. Ophthalmol. Vis. Sci. 44:2422.
7. Vuillermoz, B. et al. (2004) Exp. Cell Res. 296:294.
8. Nikitovic, D. et al. (2008) FEBS J. 275:350.
9. D’Onofrio, M.F. et al. (2008) Biochem. Biophys. Res. Commun. 365:266.
10. Ishiwata, T. et al. (2007) Oncol. Rep. 18:537.

Publications for Lumican (2846-LU)(9)

Publications using 2846-LU

• K Karamanou, M Franchi, I Proult, R Rivet, D Vynios, S Brézillon Lumican Inhibits In Vivo Melanoma Metastasis by Altering Matrix-Effectors and Invadopodia Markers Cells, 2021-04-08;10(4):. 2021-04-08 [PMID: 33917849] (Bioassay, Mouse)
• D Chen, LR Smith, G Khandekar, P Patel, CK Yu, K Zhang, CS Chen, L Han, RG Wells Distinct effects of different matrix proteoglycans on collagen fibrillogenesis and cell-mediated collagen reorganization Sci Rep, 2020-11-04;10(1):19065. 2020-11-04 [PMID: 33149218] (Cell Culture, Mouse)
• AF Asega, MC Menezes, D Trevisan-S, D Cajado-Car, L Bertholim, AK Oliveira, A Zelanis, SMT Serrano Cleavage of proteoglycans, plasma proteins and the platelet-derived growth factor receptor in the hemorrhagic process induced by snake venom metalloproteinases Sci Rep, 2020-07-31;10(1):12912. 2020-07-31 [PMID: 32737331] (Bioassay, Snake)
• X Li, Y Kang, D Roife, Y Lee, M Pratt, MR Perez, B Dai, EJ Koay, JB Fleming Prolonged exposure to extracellular lumican restrains pancreatic adenocarcinoma growth Oncogene, 2017-05-22;0(0):. 2017-05-22 [PMID: 28534517] (Bioassay, Human)
• K Karamanou, M Franchi, Z Piperigkou, C Perreau, FX Maquart, DH Vynios, S Brézillon Lumican effectively regulates the estrogen receptors-associated functional properties of breast cancer cells, expression of matrix effectors and epithelial-to-mesenchymal transition Sci Rep, 2017-03-23;7(0):45138. 2017-03-23 [PMID: 28332606] (Bioassay, Human)
• Transforming Growth Factor-? Limits Secretion of Lumican by Activated Stellate Cells within Primary Pancreatic Adenocarcinoma Tumors Clin Cancer Res, 2016-04-28;0(0):. 2016-04-28 [PMID: 27126993] (Bioassay, Human)
• Zhang Y, Mao X, Schwend T, Littlechild S, Conrad G Resistance of corneal RFUVA-cross-linked collagens and small leucine-rich proteoglycans to degradation by matrix metalloproteinases. Invest Ophthalmol Vis Sci, 2013-02-05;54(2):1014-25. 2013-02-05 [PMID: 23322569] (Enzyme Assay, Human)
• Krishnan A, Li X, Kao W, Viker K, Butters K, Masuoka H, Knudsen B, Gores G, Charlton M Lumican, an extracellular matrix proteoglycan, is a novel requisite for hepatic fibrosis. Lab Invest, 2012-09-24;92(12):1712-25. 2012-09-24 [PMID: 23007134] (Bioassay, Rat)
• Seomun Y, Joo CK Lumican induces human corneal epithelial cell migration and integrin expression via ERK 1/2 signaling. Biochem. Biophys. Res. Commun., 2008-05-12;372(1):221-5. 2008-05-12 [PMID: 18477477] (Bioassay, Human)

Bioinformatics

• Gene Symbol: LUM
• Uniprot:
  • P51884()